نتایج جستجو برای: alcoholic steatohepatitis nash

تعداد نتایج: 51208  

Journal: :European review for medical and pharmacological sciences 2005
E Capristo L Miele A Forgione V Vero S Farnetti G Mingrone A V Greco G Gasbarrini A Grieco

BACKGROUND AND OBJECTIVES Metabolic alterations are a common feature in patients affected by non-alcoholic steato-hepatitis (NASH). A strong correlation exists between overweight, in particular visceral fat accumulation, and prevalence of NASH, especially in men. Thus, diet-induced weight loss represents a fundamental tool in disease management of these patients. The aim of the present study wa...

Journal: :Journal of gastroenterology and hepatology 2016
Sara Heebøll Rime Bahij El-Houri Ylva Erika Kristina Hellberg David Haldrup Steen Bønløkke Pedersen Niels Jessen Lars Porskjaer Christensen Henning Grønbaek

BACKGROUND AND AIM Non-alcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease with few therapeutic options. Resveratrol (RSV) prevents the development of steatosis in a number of experimental fatty liver (non-alcoholic fatty liver [NAFL]) models, but the preventive or therapeutic effects on experimental NASH are not yet clarified, and clinical results on non-alcoholic fatt...

Journal: :Molecular metabolism 2016
Torsten Schröder David Kucharczyk Florian Bär René Pagel Stefanie Derer Sebastian Torben Jendrek Annika Sünderhauf Ann-Kathrin Brethack Misa Hirose Steffen Möller Axel Künstner Julia Bischof Imke Weyers Jörg Heeren Dirk Koczan Sebastian Michael Schmid Senad Divanovic Daniel Aaron Giles Jerzy Adamski Klaus Fellermann Hendrik Lehnert Jörg Köhl Saleh Ibrahim Christian Sina

OBJECTIVE Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is associated with an enhanced risk for liver and cardiovascular diseases and mortality. NAFLD can progress from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH). However, the mechanisms predisposing to this progression remain undefined. Notably, hepatic mitochondrial dysfunction is ...

2016
Davide Povero Ariel E Feldstein

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in adults and children worldwide. NAFLD has become a severe health issue and it can progress towards a more severe form of the disease, the non-alcoholic steatohepatitis (NASH). A combination of environmental factors, host genetics, and gut microbiota leads to excessive accumulation of lipids in ...

2013
Michiko Itoh Hideaki Kato Takayoshi Suganami Kuniha Konuma Yoshio Marumoto Shuji Terai Hiroshi Sakugawa Sayaka Kanai Miho Hamaguchi Takahiro Fukaishi Seiichiro Aoe Kazunari Akiyoshi Yoshihiro Komohara Motohiro Takeya Isao Sakaida Yoshihiro Ogawa

Although macrophages are thought to be crucial for the pathogenesis of chronic inflammatory diseases, how they are involved in disease progression from simple steatosis to non-alcoholic steatohepatitis (NASH) is poorly understood. Here we report the unique histological structure termed "hepatic crown-like structures (hCLS)" in the mouse model of human NASH; melanocortin-4 receptor deficient mic...

Journal: :Liver international : official journal of the International Association for the Study of the Liver 2017
Pierre Bedossa

Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of lesions ranging from steatosis (Non-alcoholic Fatty Liver or NAFL) to a complex pattern with hepatocellular injury and inflammation (non-alcoholic steatohepatitis; NASH) in the absence of alcohol intake. However, it is increasingly clear that intermediate patterns may exist. The histopathological evaluation of liver biopsy samples i...

Journal: :International journal of molecular medicine 2012
Jun Kato Masahiko Koda Manabu Kishina Shiho Tokunaga Tomomitsu Matono Takaaki Sugihara Masaru Ueki Yoshikazu Murawaki

Non-alcoholic steatohepatitis (NASH) is the hepatic manifestation of a metabolic syndrome characterized by accumulation of hepatic fat, inflammation and varying degrees of fibrosis. Angiotensin (AT)-II has been reported to play a role in the establishment of NASH. This study examined the effects of an AT-II receptor blocker, irbesartan, on NASH using fatty liver Shionogi (FLS)-ob/ob male mice a...

2017
Adnan Said Aiman Ghufran

Non-alcoholic fatty liver disease (NAFLD) associated hepatocellular carcinoma (HCC) incidence is increasing worldwide, paralleling the obesity epidemic. Although most cases are associated with cirrhosis, HCC can occur without cirrhosis in NAFLD. Diabetes and obesity are associated risk factors for HCC in patients. Given the sheer magnitude of the underlying risk factors (diabetes, obesity, non-...

2016
Xiao-Lin Liu Qin Pan Rui-Nan Zhang Feng Shen Shi-Yan Yan Chao Sun Zheng-Jie Xu Yuan-Wen Chen Jian-Gao Fan

AIM To assess disease-specific circulating microRNAs (miRNAs) in non-alcoholic steatohepatitis (NASH) patients. METHODS A total of 111 biopsy-proven non-alcoholic fatty liver disease (NAFLD) or chronic hepatitis B (CHB) patients and healthy controls from mainland China were enrolled to measure their serum levels of miR-122, -125b, -146b, -16, -21, -192, -27b and -34a. The correlations between...

2017
Ahad Eshraghian

The main treatment of patients with non-alcoholic fatty liver disease (NAFLD) is life style modification including weight reduction and dietary regimen. Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD patients with non-alcoholic steatohepatitis (NASH) who cannot achieve goals of life style modificatio...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید